Marciana Laster

Dr. Marciana Laster


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
MLMarciana Laster
Marciana Laster
RPRenata C Pereira
Renata C Pereira
KNKathleen Noche
Kathleen Noche
BGBarbara Gales
Barbara Gales
ISIsidro Salusky
Isidro Salusky
LALauren V Albrecht
Lauren V Albrecht
The pathophysiology of chronic kidney disease-mineral and bone disorder (CKD-MBD) is not well understood. Specific factors secreted by osteocytes are elevated in the serum of adults and pediatric patients with CKD-MBD, including FGF-23 and sclerostin, a known inhibitor of the Wnt signaling pathway. The molecular mechanisms that promote bone disease during the progression of CKD are incompletely understood. In this study, we performed a cross-sectional analysis of 87 pediatric patients with pre-dialysis CKD and post-dialysis (CKD 5D). We assessed the associations between serum and bone sclerostin levels and biomarkers of bone turnover and bone histomorphometry. We report that serum sclerostin levels were elevated in both early and late CKD. Higher circulating and bone sclerostin levels were associated with histomorphometric parameters of bone turnover and mineralization. Immunofluorescence analyses of bone biopsies evaluated osteocyte staining of antibodies towards the canonical Wnt target, β-catenin, in the phosphorylated (inhibited) or unphosphorylated (active) forms. Bone sclerostin was found to be colocalized with phosphorylated β-catenin, which suggests that Wnt signaling was inhibited. In patients with low serum sclerostin levels, increased unphosphorylated “active” β-catenin staining was observed in osteocytes. These data provide new mechanistic insight into the pathogenesis of CKD-MBD and suggest that sclerostin may offer a potential biomarker or therapeutic target in pediatric renal osteodystrophy.

19 May 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MLMarciana Laster
Marciana Laster
BRBryce Rowan
Bryce Rowan
HCHua-Chang Chen
Hua-Chang Chen
TSTae-Hwi Schwantes-An
Tae-Hwi Schwantes-An
XSXin Sheng
Xin Sheng
CRCassianne Robinson-Cohen
Cassianne Robinson-Cohen
Context Chronic kidney disease (CKD) causes multiple interrelated disturbances in mineral metabolism. Genetic studies in the general population have identified common genetic variants associated with circulating phosphate, calcium, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23). Objective In this study we aimed to discover genetic variants associated with circulating mineral markers in CKD. Methods We conducted candidate single-nucleotide variation (SNV) analysis in 3027 participants in the multiethnic Chronic Renal Insufficiency Cohort (CRIC) to determine the associations between SNVs and circulating levels of mineral markers. Results SNVs adjacent to or within genes encoding the regulator of G protein–coupled signaling 14 (RGS14) and the calcium-sensing receptor (CASR) were associated with levels of mineral metabolites. The strongest associations (P < .001) were at rs4074995 (RGS14) for phosphate (0.09 mg/dL lower per minor allele) and FGF23 (8.6% lower), and at rs1801725 (CASR) for calcium (0.12 mg/dL higher). In addition, the prevalence of hyperparathyroidism differed by rs4074995 (RGS14) genotype (chi-square P < .0001). Differential inheritance by race was noted for the minor allele of RGS14. Expression quantitative loci (eQTL) analysis showed that rs4074995 was associated with lower RGS14 gene expression in glomeruli (P = 1.03 × 10–11) and tubules (P = 4.0 × 10–4). Conclusion We evaluated genetic variants associated with mineral metabolism markers in a CKD population. Participants with CKD and the minor allele of rs4074995 (RGS14) had lower phosphorus, lower plasma FGF23, and lower prevalence of hyperparathyroidism. The minor allele of RGS14 was also associated with lower gene expression in the kidney. Further studies are needed to elucidate the effect of rs4074995 on the pathogenesis of disordered mineral metabolism in CKD.

23 October 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
MLMarciana Laster
Marciana Laster
MDMichelle Denburg
Michelle Denburg
YOYusuke Okuda
Yusuke Okuda
JKJuhi Kumar
Juhi Kumar
SFSusan Furth
Susan Furth
ISIsidro B. Salusky
Isidro B. Salusky
Studies in healthy children have demonstrated racial‐ethnic differences in bone markers and bone outcomes including fractures. At present, limited studies have evaluated the impact of race and ethnicity on bone markers and fractures within the pediatric chronic kidney disease population. In a cohort study of 762 children between the ages of 1.5 years and 18 years, with CKD stages 1‐4 from the CKD in children (CKiD) cohort, the relationship between racial‐ethnic group and bone markers (parathyroid hormone [PTH], 25‐hydroxyvitamin D [25‐OHD], 1,25‐dihydroxyvitamin D [1,25(OH)2D] and c‐terminal fibroblast growth factor [FGF23]) was determined using linear mixed models. Additionally, logistic regression was used to evaluate racial‐ethnic differences in prevalent fracture upon study entry. African American race was associated with 23% (confidence interval [CI] 2.5% to 47.7%, p=0.03) higher PTH levels, 33.1% (CI: ‐39.7% to ‐25.7%, p<0.0001) lower 25‐OHD levels, and no difference in c‐terminal FGF23 or 1,25(OH)2D levels when compared to Caucasians. Hispanic ethnicity was associated with 15.9% (CI: ‐28.3% to ‐1.5%, p=0.03) lower c‐terminal FGF23 levels and 13.8% (CI: ‐22.2% to ‐4.5%, p=0.005) lower 25‐OHD levels when compared to Caucasians. African‐American and Hispanic children had a 74% (odds ratio [OR]: 0.26, CI: 0.14, 0.49, p=0.001) and 66% (OR: 0.34, CI: 0.17, 0.65, P<0.0001) lower odds of any fracture than Caucasian children at study entry, respectively. Race and ethnicity are associated with differences in bone markers and despite lower 25‐OHD levels, both African American and Hispanic children with CKD reported a lower prevalent fracture history than Caucasian children. The current findings in the CKD population are similar to racial‐ethnic differences described in healthy children. Additional studies are needed to better understand how these differences might impact the management of pediatric CKD‐MBD.

1 October 2019 in Bone
Verified
Journal Article
Closed access
MLMarciana Laster
Marciana Laster
RPRenata C. Pereira
Renata C. Pereira
ISIsidro B. Salusky
Isidro B. Salusky

8 July 2022 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
RPReut Pagi
Reut Pagi
OYOra Yadin
Ora Yadin
KWKatherine Wesseling-Perry
Katherine Wesseling-Perry
KNKeith Norris
Keith Norris
MLMarciana Laster
Marciana Laster
Background: Black adults with chronic kidney disease (CKD) have higher rates of hypertension as compared to White adults with CKD. Little is known of how race and ethnicity associate with the prevalence of hypertension in pediatric CKD patients. The aim was to compare ambulatory blood pressure monitoring (ABPM) results for patients with CKD enrolled in the Chronic Kidney Disease in Children (CKiD) study across racial-ethnic groups.Methods: Patients from the CKiD study who identified as non-Hispanic White, non-Hispanic Black, or Hispanic were included to analyze differences in ABPM results across these racial-ethnic groups. The outcomes were fitted using 3 progressively adjusted models.Results: This study included 501 CKiD participants with at least one successful ABPM study. Compared to White participants, Black participants had 4.2 mmHg higher mean sleep systolic blood pressure and 2.7 mmHg higher mean sleep diastolic blood pressure (p = 0.001 andp = 0.004, respectively). Additionally, Black participants had higher odds of abnormal wake systolic load (OR1.88, 1.21–2.91,p = 0.005), wake diastolic load (OR1.68, 1.03–2.73,p = 0.04), sleep systolic load (OR2.19, 1.36–3.5,p = 0.001), sleep diastolic load (OR2.01, 1.28–3.15,p = 0.002), systolic non-dipping (OR2.02, 1.31–3.10,p = 0.001), and diastolic non-dipping (OR2.69, 1.60–4.51,p < 0.001). Compared to White participants, Hispanic participants demonstrated only a lower sleep diastolic load (OR0.54, 0.31–0.95,p = 0.03).Conclusions: Black children with CKD have higher absolute nocturnal blood pressures and higher rates of abnormal dipping. Further studies are needed to determine the etiology of these differences and the clinical implications of racial-ethnic differences in ABPM outcomes within the pediatric CKD population.Graphical A higher resolution version of the Graphical abstract is available as Supplementary information

29 September 2018 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
MLMarciana Laster
Marciana Laster
MSMelissa Soohoo
Melissa Soohoo
ESElani Streja
Elani Streja
RERobert Elashoff
Robert Elashoff
SJStephanie Jernigan
Stephanie Jernigan
Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Kamyar Kalantar-Zadeh
Studies in healthy pediatric populations and adults treated with dialysis demonstrate higher parathyroid hormone (PTH) and lower 25-hydroxyvitamin D levels in African-Americans. Despite these findings, African-Americans on dialysis demonstrate greater bone strength and a decreased risk of fracture compared to the Caucasian dialysis population. The presence of such differences in children and young adult dialysis patients is unknown.